鐧界粏鑳炰粙绱?2锛圛L-2锛夋槸涓€绉?33涓皑鍩洪吀绯栬泲鐧斤紝鍏锋湁涓€涓垎瀛愬唴浜岀～閿拰绯栧熀鍖栦慨楗般€侷L2鐢辨椿鍖栫殑T缁嗚優鍒嗘硨锛岃瀵兼椿鍖栫殑T缁嗚優銆佽嚜鐒舵潃浼ょ粏鑳炲拰娣嬪反鍥犲瓙娲诲寲鐨勬潃浼ょ粏鑳炲娈栧拰鎴愮啛銆侷L-2杩樺埡婵€鎶椾綋浜х敓B缁嗚優鐨勫娈栵紝婵€娲讳腑鎬х矑缁嗚優锛岃瀵煎崟鏍哥粏鑳炲垎娉孖FN-纬鍜孴NF-伪鍜?尾銆傛澶栵紝鐮旂┒琛ㄦ槑锛孖L-2鏄縺娲昏瀵肩殑缁嗚優鍑嬩骸鎵€蹇呴渶鐨勶紝杩欐槸鍏嶇柅绯荤粺涓竴绉嶉噸瑕佺殑绋虫€佹満鍒讹紝涓庣淮鎸佸鍛ㄥ鑷韩鎶楀師鐨勮€愬彈鏈夊叧銆侷L-2淇冭繘T缁嗚優澧炴畺锛屽挨鍏舵槸骞肩鐨凾缁嗚優銆侷L-2閫氳繃涓€涓敱IL-2銆両L-2R伪锛圕D25锛夈€両L-2R尾鍜孖L-2R纬缁勬垚鐨勫洓绾ч珮浜插拰鍔涘彈浣撳鍚堜綋鍦ㄦ椿鍖栫殑T缁嗚優涓婁紶閫掍俊鍙枫€傚辜绋氱殑T缁嗚優瀵笽L-2鐩稿涓嶆晱鎰燂紝鍥犱负瀹冧滑鍙〃杈惧皯閲忕殑IL-2R尾鍜孖L-2R纬锛屼絾鍦–D25琛ㄨ揪鍚庤幏寰楁晱鎰熸€э紝CD25鎹曡幏缁嗚優鍥犲瓙骞跺皢鍏跺憟鐜扮粰IL-2R尾鍜孖L-2R纬鍙椾綋銆侟br/>

鏈骇鍝佺敱CHO缁嗚優绋宠浆鏍〃杈撅紝楂樼函搴︼紝楂樻椿鎬э紝鏃犲姩鐗╂簮鎬ф薄鏌撱€侟/p>

璁㈣揣淇℃伅
浜у搧璐у彿	CK1001-His
浜у搧瑙勬牸	100ug / 1mg / 10mg
浜у搧淇℃伅
CAS	110942-02-4
琛ㄨ揪瀹夸富:	CHO缁嗚優
鍒嗗瓙閲廁	16.2kDa
鏍囩锛欬/span>	C绔疕is Tag
褰㈡€?	鍐诲共绮 / 娑蹭綋
绾寲鏂规硶:	灞傛瀽绾寲
缂撲綋浣撶郴:	1脳PBS, pH7.4
淇濆瓨鏉′欢锛欬/span>	-20鈩儈-80鈩冿紙2骞达級
浜у搧璐ㄩ噺
鏃犺弻妫€娴嬶細	鍚堟牸
鏀師浣撴娴嬶細	鍚堟牸
鍐呮瘨绱犳按骞筹細	<0.01 EU/ug
绾害锛欬/span>	鈮?8%锛岄噰鐢 SDS-PAGE 鍒嗘瀽锛堝浘1锛夊強HPLC鍒嗘瀽
娲绘€э細	淇冨皬榧燙TLL-2 缁嗚優澧炴畺娴嬪畾锛孍D50涓?.05-0.1ng/ml锛堝浘2锛夛紝鐩稿簲鐨勬瘮娲绘€ >1脳107IU/mg

鍥?锛氶噸缁勪汉鐧戒粙绱? Recombinant Human IL-2锛圚is Tag锛 绾害妫€娴嬬粨鏋滐紝宸﹀浘锛欬span style="margin: 0px; padding: 0px; -webkit-tap-highlight-color: transparent; outline: 0px; max-width: 100%; color: rgb(0, 0, 0); font-family: 寰蒋闆呴粦, sans-serif; letter-spacing: 0.578px; text-align: left; box-sizing: border-box !important; overflow-wrap: break-word !important;">SDS-PAGE锛堟牱鍝丯R锛岄潪杩樺師锛屾牱鍝丷锛岃繕鍘燂級锛涘彸鍥撅細SEC-HPLC

鍥?锛氱煡绂炬嘲鍏嬮噸缁勪汉鐧戒粙绱? Recombinant Human IL-2锛圚is Tag锛 鐢熺墿娲绘€ф娴嬬粨鏋滐紝娲绘€?nbsp;>1脳10⁷IU/mg

鍙傝€冩枃鐚?/strong>

1. Wang W, Yuan T, Ma L, et al. Hepatobiliary Tumor Organoids Reveal HLA Class I Neoantigen Landscape and Antitumoral Activity of Neoantigen Peptide Enhanced with Immune Checkpoint Inhibitors. Adv Sci (Weinh). 2022;9(22):e2105810. doi:10.1002/advs.202105810

2. Xue D, Hsu E, Fu YX, Peng H. Next-generation cytokines for cancer immunotherapy. Antib Ther. 2021;4(2):123-133. Published 2021 Jun 25. doi:10.1093/abt/tbab014

3. Marsman C, Verhoeven D, Koers J, et al. Optimized Protocols for In-Vitro T-Cell-Dependent and T-Cell-Independent Activation for B-Cell Differentiation Studies Using Limited Cells. Front Immunol. 2022;13:815449. Published 2022 Jun 29. doi:10.3389/fimmu.2022.815449